HER2 Breast Cancer

Studies presented at the 2013 Breast Cancer Symposium investigated the efficacy and safety of various approaches to the treatment of HER2-positive breast cancer.

An analysis of the T-PAS expanded access study of T-DM1 in previously treated HER2+ metastatic breast cancer confirmed existing information on the safety of the combination, and observed significant clinical activity in a patient population that averaged seven prior therapies.

Denise A. Yardley, MD, Senior Investigator, Sarah Cannon Research Institute, discusses an expanded access study of T-DM1 in previously treated HER2-positive metastatic breast cancer.

Dual HER2-targeted neoadjuvant therapy for early breast cancer did not significantly improve the pCR rate compared with a single anti-HER2 agent plus chemotherapy.

Max S. Wicha, MD, was part of the first team to discover stem cells in breast cancer, and he is among the most highly cited investigators in the field of cancer stem cells.

The mechanism of action of trastuzumab (Herceptin), a monoclonal antibody that is approved for the treatment of early-stage breast cancer that is HER2-positive.

Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses assays and intrinsic subtypes of breast cancer.

Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, discusses the changing view of anti-HER2 therapies for patients with breast cancer.